1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
Acne Vulgaris: Opportunity Analysis and Forecasts to 2026

Acne Vulgaris: Opportunity Analysis and Forecasts to 2026

  • March 2018
  • 159 pages
  • ID: 5404417
  • Format: PDF
  • GlobalData
Up to $9896 off Until Oct 31st 2020

Summary

Table of Contents

Search Inside

Acne Vulgaris: Opportunity Analysis and Forecasts to 2026

Summary
Acne vulgaris (acne) is currently one of the most common and well-established dermatology conditions, affecting around 90% of the world’s population at some point in their lifetime.The disease is a chronic, inflammatory dermatological condition of the pilosebaceous gland of the skin with a multifactorial pathogenesis.

It is usually initiated during puberty by hormonal changes and further exacerbated by genetic factors.

GlobalData estimates the 2016 global acne therapeutic sales to total approximately $2.9 billion across the seven major pharmaceutical markets (7MM) covered within this report: the US, France, Germany, Italy, Spain, UK, and Japan. The US contributes 90% of these sales, generating an estimated $2.6 billion in 2016. The 5EU generated $219M in sales, with Germany being the largest market, accounting for an estimated $62.4M in sales in 2016.

By the end of the forecast period in 2026, acne sales are forecast to reach over $4.1 billion, growing at a compound annual growth rate (CAGR) of 3.5% over the 10-year forecast period. The majority of sales will come from the US, which will maintain its 2016 lead and command 92% of the market in 2026. A substantial amount of growth in that market is attributed to the rapid uptake of Galderma’sEpiduo (benzoyl peroxide and adapalene) for moderate patients and the continued success of isotretinoin. The anticipated launches of AOBiome’s B244 and Novan’s SB204 will add new molecular entities to the acne market for the first time in approximately 30 years. Paratek’s and Allergan’s Seysara, Foamix Pharmaceuticals’ FMX-101, and Cassiopea’sWinlevi are also expected to launch during the forecast period. Together, these late-stage pipeline products are expected to add approximately $956M in sales to the acne market in 2026.

The report "Acne Vulgaris: Opportunity Analysis and Forecasts to 2026", provides overview of acne vulgaris, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Key highlights of the report -
- The greatest driver of growth in the global acne market will be the launches of five pipeline therapies during the forecast period. The entry of these anticipated drugs with novel mechanisms of action, including AOBiome’s B244, will be subject to rapid uptake.
- The appreciation of compliance as a major factor that contributes to the success or failure of treatments, thus affecting sales. Galderma launched the TAP program to improve compliance of its key product, Epiduo. Increased patient and provider awareness will also help increase patient share of many marketed therapies during the forecast period.

Companies mentioned in this report: Allergan, Almirall, AndroScience, AOBiome, Astellas, Bayer, Botanix Pharmaceuticals, Braintree Laboratories , CassiopeaSpA, Celtaxys, Common Pharma, CutaneaLife Sciences, Dermira, Dow Pharma, Elorac Inc., Foamix Pharmaceuticals, Galderma, GSK, GuilianiSpA, Guthy-Renker, Medicis Pharmaceutical, Melinta Therapeutics, Mimetica, Novan, Novartis, Paratek, Photocure, Roche, Sanofi, SignumDermalogix, Stiefel Laboratories, Sun Pharmaceutical, Taro Pharmaceutical Industries, Valeant, Vyome Biosciences, XBiotech

Scope
- Overview of acne vulgaris, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized acne therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the acne therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global acne therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global acne therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global acne therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global acne therapeutics market from 2016-2026.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Acne Vulgaris - Pipeline Review, H1 2020

  • $ 2000
  • April 2020
  • 224 pages

Acne Vulgaris - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2020, provides an overview of the Acne Vulgaris ...

  • World
  • United States
  • Acne Treatment
  • Industry analysis
  • Drug Approval
  • Pharmaceutical Registrations

Global Acne Drugs Market 2016-2020 $ 2500 November 2015


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on